⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1087110 | 1.00 | — | — | |
| SCHEMBL22857 | 1.00 | — | — | |
| SCHEMBL28060646 | 0.87 | TSHR (0.39) | — | |
| SCHEMBL14619651 | 0.85 | — | — | |
| SCHEMBL15925286 | 0.85 | — | — | |
| SCHEMBL2980359 | 0.85 | — | — | |
| SCHEMBL2304860 | 0.83 | TSHR (0.50) | — | |
| SCHEMBL772803 | 0.82 | — | — | |
| SCHEMBL7912566 | 0.82 | — | — | |
| SCHEMBL4754346 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217099-A1 | INHIBITORS FOR HYDROGEN EMBRITTLEMENT AND METHODS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025217091-A1 | ODORANTS FOR FLUIDS, ODORIZED FLUIDS, METHODS, AND SYSTEMS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2025-10-16 | — | — | WO | disclosed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11964938-B2 | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | CELON PHARMA S.A. (PL) | 2024-04-23 | — | — | US | disclosed |
| EP-3737470-B9 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | Celon Pharma Sa (PL) | 2024-03-13 | — | — | EP | disclosed |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339851-A1 | CXCR6 SULFONAMIDE COMPOUNDS | CHEMOCENTRYX, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339851-A1 | CXCR6 SULFONAMIDE COMPOUNDS | CHEMOCENTRYX, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-7304071-B2 | Protein kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1847543-A1 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-10-24 | — | — | EP | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |